Plk2 - polo-like kinase 2 Gene

Rattus norvegicus

Also known as Snk

Gene ID: 83722 | Gene type: protein coding

About Plk2

Primary_assembly 2: 41,969,176-41,974,947 forward strand.mRatBN7.2:CM026975.1

This gene has 2 transcripts (splice variants), 221 orthologues, 4 paralogues and is associated with 8 phenotypes. Biased expression in Brain (RPKM 389.), Liver (RPKM 239.2) and 9 other tissues.

Summary

Enables protein serine/threonine kinase activity. Involved in several processes, including Rap protein signal transduction; negative regulation of dendritic spine development; and regulation of synaptic plasticity. Located in dendrite. Orthologous to human PLK2 (polo like kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Plk2 Products(1)

mRNA	Protein	Name
NM_031821.2	NP_114009.1	serine/threonine-protein kinase PLK2

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	Reference	Source
enables ATPase binding	IPI IPI: Inferred from physical interaction	20802490	RGD
enables GTPase binding	IPI IPI: Inferred from physical interaction	20802490	RGD
enables clathrin heavy chain binding	IPI IPI: Inferred from physical interaction	20802490	RGD
enables protein binding	IPI IPI: Inferred from physical interaction	10523297	RGD
enables protein kinase binding	IPI IPI: Inferred from physical interaction	20802490	RGD
enables protein serine/threonine kinase activity	IDA IDA: Inferred from direct assay	18498738	RGD
enables protein-containing complex binding	IPI IPI: Inferred from physical interaction	18723513	RGD

Biological Process GO Annotation	Evidence	Reference	Source
involved in Rap protein signal transduction	IDA IDA: Inferred from direct assay	21382555	RGD
involved in Ras protein signal transduction	IDA IDA: Inferred from direct assay	21382555	RGD
involved in long-term synaptic depression	IDA IDA: Inferred from direct assay	21382555	RGD
involved in long-term synaptic potentiation	IDA IDA: Inferred from direct assay	21382555	RGD
involved in negative regulation of dendritic spine development	IMP IMP: Inferred from mutant phenotype	18723513	RGD
involved in negative regulation of excitatory postsynaptic potential	IMP IMP: Inferred from mutant phenotype	20802490	RGD
involved in negative regulation of protein localization to cell surface	IMP IMP: Inferred from mutant phenotype	20802490	RGD
involved in positive regulation of proteasomal ubiquitin-dependent protein catabolic process	IMP IMP: Inferred from mutant phenotype	18723513	RGD
involved in positive regulation of receptor internalization	IMP IMP: Inferred from mutant phenotype	20802490	RGD
involved in protein phosphorylation	IDA IDA: Inferred from direct assay	21382555	RGD
involved in regulation of synaptic plasticity	IDA IDA: Inferred from direct assay	21382555	RGD
involved in regulation of synaptic plasticity	IMP IMP: Inferred from mutant phenotype	18498738	RGD
involved in regulation protein catabolic process at postsynapse	IDA IDA: Inferred from direct assay	14576440	RGD
involved in regulation protein catabolic process at postsynapse	IEP IEP: Inferred from expression pattern	14576440	RGD
involved in regulation protein catabolic process at postsynapse	IMP IMP: Inferred from mutant phenotype	14576440	RGD

Cellular Component GO Annotation	Evidence	Reference	Source
located in dendrite	IDA IDA: Inferred from direct assay	10523297	RGD
is active in postsynapse	IDA IDA: Inferred from direct assay	14576440	RGD
is active in postsynapse	IMP IMP: Inferred from mutant phenotype	14576440	RGD

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Plk2 Protein Structure

STKc_PLK2

POLO_box_1

POLO_box_2

0
200
400
600
682 a.a.

Protein Preferred Names

Protein Names

serine/threonine-protein kinase PLK2

PLK-2	polo-like kinase 1
serine/threonine-protein kinase SNK	serum-inducible kinase

Related Agents

Approval

Bioactive Molecules (2)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-12137	Volasertib	Inhibitor	99.41%	Yes
HY-12137A	Volasertib trihydrochloride	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (7)

Cat. No.	Product Name	Effect	Purity	Phase
HY-12037A	Rigosertib	Inhibitor	98.52%	Phase 3
HY-12037	Rigosertib sodium	Inhibitor	99.57%	Phase 3
HY-50698	BI 2536	Inhibitor	99.95%	Phase 2
HY-147298	Plogosertib	Inhibitor	99.95%	Phase 2
HY-15160	TAK-960	Inhibitor	99.75%	Phase 1
HY-15160B	TAK-960 dihydrochloride	Inhibitor	99.19%	Phase 1
HY-15160A	TAK-960 hydrochloride	Inhibitor	/	Phase 1

Pre-clinical Phase

Bioactive Molecules (5)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-100789	ON1231320	Inhibitor	99.24%	Unkown
HY-108597	TC-S 7005	Inhibitor	99.56%	Unkown
HY-12134	Poloxin	Inhibitor	98.01%	Unkown
HY-115589	YLT-11	Inhibitor	/	Unkown
HY-149100	PLK1-IN-6	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Plk2	NCBI	NCBI:10769

Name
Email *

	Sorry, but the email address you supplied was invalid.